| Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma (NCT05119036) | Indiana University | 2022-05-12 |
| A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) (NCT05307939) | Memorial Sloan Kettering Cancer Center | 2022-03-24 |
| Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study (NCT04900623) | Jonathan Schoenfeld, MD, MPH | 2021-07-02 |
| This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols. (NCT05061940) | Repertoire Immune Medicines | 2021-05-05 |
| Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC (NCT04260126) | PDS Biotechnology Corp. | 2021-03-29 |
| Improving Detection and Early Action for HPV-positive Oropharynx Cancer (NCT04871490) | Brigham and Women's Hospital | 2021-03-24 |
| Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV (NCT04255849) | Weill Medical College of Cornell University | 2021-02-23 |
| Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer (NCT04502407) | Cedars-Sinai Medical Center | 2021-02-16 |
| Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer (NCT04444869) | University of Missouri-Columbia | 2020-09-28 |
| Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (NCT04301011) | Turnstone Biologics, Corp. | 2020-06-02 |
| Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients (NCT04001413) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2019-09-17 |
| A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (NCT03978689) | Cue Biopharma | 2019-07-30 |
| Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced Oropharyngeal Cancer Undergoing Chemoradiation Therapy (NCT03611205) | Ohio State University Comprehensive Cancer Center | 2019-07-01 |
| Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer (NCT03601507) | University of Arizona | 2019-03-11 |
| Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma (NCT03215719) | NYU Langone Health | 2017-10-18 |
| Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck (NCT02113878) | Dana-Farber Cancer Institute | 2014-09-29 |
| ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer (NCT02002182) | Andrew Sikora | 2013-12-01 |
| Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (NCT01855451) | Trans Tasman Radiation Oncology Group | 2013-06-03 |